Background {#Sec1}
==========

Sepsis and septic shock remain one of the deadliest diseases in intensive care units worldwide \[[@CR1], [@CR2]\] and are estimated to contribute to more than one third of all hospital deaths \[[@CR3]\]. Despite the magnitude of the sepsis burden, efforts to develop new treatments have been largely unsuccessful \[[@CR4], [@CR5]\]. Therefore, sepsis management continues to rely on source control, supportive measures, and adequate antibiotic treatment. This includes adequate antibiotic dosing to prevent toxicity and inadequate exposure.

Despite the importance of antibiotic dosing, antibiotic exposure is well known to be frequently inadequate in intensive care patients \[[@CR6]--[@CR8]\]. The DALI study showed that less than 50% of patients treated for infection with β-lactam antibiotics achieved their preferred pharmacokinetic target \[[@CR8]\]. Similar observations have been reported in other studies for beta-lactam antibiotics \[[@CR9], [@CR10]\], as well as for fluoroquinolones \[[@CR11], [@CR12]\]. More importantly, the DALI study showed aberrant serum concentrations were associated with poorer outcome in clinical patients \[[@CR8]\]. The rationale that underdosing leads to ineffective pathogen eradication seems probable for other antibiotics as well.

Admittedly, adequate antibiotic dosing for critically ill patients is challenging. Intensive care patients have markedly altered and variable pharmacokinetic parameters for antibiotics as compared to healthy individuals or less severely ill patients. Organ dysfunction, abnormal fluid balances, altered hemodynamics, and organ replacement therapy can severely impact dosing requirements \[[@CR13]\]. However, guidelines fail to provide recommendations on dose adaptation or dose personalization in these patients \[[@CR14]\]. Therefore, prescribing antibiotics routinely follows a one-size-fits-all principle.

Therapeutic drug monitoring may provide guidance, but is usually only provided for aminoglycosides \[[@CR15]\] and the glycopeptide vancomycin \[[@CR16]\], but not for other antibiotics. In addition, this guidance requires drug sampling and can therefore not be used at the start of antibiotic treatment, paradoxically when adequate dosing may be most important. Fully automated systems that provide real-time bedside advice and are integrated with the electronic patient record could be a solution, but require further development and clinical validation \[[@CR17]\].

As a consequence, adequate pharmacokinetic knowledge remains pivotal to optimize antibiotic dosing at the bedside of the critically ill. It is currently not known whether the level of knowledge on pharmacometric principles among intensive care professionals is sufficient. Our hypothesis was that there is room for improvement given the signals of frequent inadequate antibiotic exposure in the critically ill. To test our hypothesis, we set out to assess the level of clinically relevant knowledge on pharmacokinetic principles governing antibiotic dosing in the setting of intensive care medicine using an expert-validated questionnaire. As a corollary, this questionnaire may serve as a validated educational tool. Therefore, we encourage readers to take the questionnaire themselves.

Methods {#Sec2}
=======

In May 2018, we set up a cross-sectional study by sending out a questionnaire testing the level of knowledge on pharmacometric principles governing antibiotic dosing in the critically ill by electronic mail. Approximately 20,000 healthcare professionals in the field of intensive care medicine were approached using the professional networks of the authors and the database of the international fluid academy (iFAD) days meeting. iFAD comprises of an international collaboration group with the aim of improving outcomes in the critically ill through fluid management, organ support, and monitoring. Attendees include nurses and critical care specialists.

Population {#Sec3}
----------

Target populations for the questionnaires were intensivists, residents, fellows, and intensive care nurses. No patients were involved in this study. For the purpose of this study, intensivist was defined as a medical specialist in critical care medicine. Fellows were defined as physicians with a dedicated program towards national or international accreditation as an intensivist. Residents were defined as all other junior physicians working in intensive care medicine. As considerable differences in medical postgraduate programs exist among countries, respondents themselves were asked to select the category most appropriate to them \[[@CR18]--[@CR21]\].

Privacy and consent {#Sec4}
-------------------

Only individuals who consented to receive electronic mail related to intensive care medicine were approached. Recipients were asked to further disseminate the questionnaire in their professional network at their own discretion to yield more responses. All intensive care professionals that chose to respond provided written informed consent for use of their data, in compliance with the General Data Protection Regulation \[[@CR22]\]. Participation was anonymous, and internet protocol addresses were not stored. We did collect additional data including date, time, and duration of questionnaire completion, age, years of work experience, hospital, and country. For privacy reasons, data on age and work experience were collected in discretized form using brackets and participants were not obliged to provide information on hospital and country.

Questions {#Sec5}
---------

All questions were specifically developed for this questionnaire and designed to cover the clinically relevant topics related to antibiotic pharmacokinetics in the setting of intensive care medicine. The core competencies defined by the Competency-Based Training in Intensive Care Medicine in Europe (CoBaTrICE) collaboration provided a reference standard for these topics \[[@CR23]\]. This yielded 12 questions, which can be found in Table [1](#Tab1){ref-type="table"} together with the answer key. The relationship between the questions and the CoBaTrICE collaboration and a review by Roberts et al. \[[@CR13]\] can be found in the Additional file [1](#MOESM1){ref-type="media"}. Underlying principles and concise background for these questions can be found in Box 1. The maximum number of possible answers varied, and questions with multiple answers were allowed. No open questions were used for ease of automated scoring. Participants were asked to refrain from using other resources to fill out the questions and were asked not to discuss questions with colleagues that had not yet participated in the survey. The questionnaire contained a control question to verify whether additional sources such as colleagues, textbooks, or the Internet were used.Table 1Characteristics of the respondentsNurseResidentFellowIntensivistTotalRespondents (\#)1541981699271448Age (mean, yrs)41.133.138.344.642Work Experience (mean, yrs)10.72.95.311.19.3Time to completion (mean, min)14.912.313.213.813.6From European countries (\#)1471921658961400*yrs* years, *min* minutes

Modified Angoff scoring {#Sec6}
-----------------------

Questions answered correctly resulted in 10 points; subquestions yielded part of the points amounting to a total of 10. To set the pass mark for the designed questions, we used a modified Angoff approach \[[@CR24]\]. In this approach, subject matter experts each attribute a minimally competent candidate (MCC) score to each of the questions. This score represents the percentage of borderline candidates (i.e., those candidates that the subject matter expert expects to just have passed the exam) that would answer these individual questions correctly. This score was corrected for guessing and adjusted to acknowledge a theoretical maximum score using the formula: corrected score = subject matter expert score × (90 − score expected by guessing) + score expected by guessing. Finally, the corrected scores for individual questions are averaged to yield the exam Angoff score. The score has been used extensively in medical education with good reliability \[[@CR25]--[@CR27]\]. It has been shown that a second round of decision-making adds little to precision; this step was therefore omitted \[[@CR28]\]. We chose members of the examination committee of the European Society of Intensive Care Medicine as our subject matter experts. Nine of these independently scored our questions. They are all experienced intensivists and responsible for the European Diploma in Intensive Care (EDIC) exams. In addition, they have ample experience in Angoff scoring. Therefore, our final pass mark can be seen as the level of knowledge that is expected from intensivists in independent practice.

Assessment of clinical relevance {#Sec7}
--------------------------------

As an additional step, we asked pharmacokinetic experts to rate our questions on clinical relevance. A PubMed ReMiner-search was conducted to identify the top 10 publishing experts in intensive care pharmacokinetics \[[@CR29]\]. Titles and abstracts were searched ("antibiotics," "intensive care," "pharmacokinetics") and sorted per author, which resulted in a list of top publishing institutions. Among these, one author from each institution was selected, which yielded six authors. The scores for these six experts were averaged and served as a correction factor for the Angoff scores. The average of all clinically relevance-corrected Angoff scores for each question formed the pass mark for the survey. All analyses were performed using Python (Python Software Foundation. Python Language Reference, version 3.6.4).

Results {#Sec8}
=======

A total of 1448 respondents completed the survey. Characteristics of the respondents are shown in Table [1](#Tab1){ref-type="table"}. Most of the respondents were intensivists (*n* = 927, 64%); the majority of whom were between 40 and 50 years of age (*n* = 383, 41%). Most of the fellows (*n* = 117, 69%) were in their thirties, compared to 31% of intensivists. Experience in the practice of intensive care medicine varied widely, with nurses and intensivists having worked in their profession the longest. The largest group has worked in the ICU between 10 and 20 years (27% and 34% of nurses and intensivists respectively). Respondents from 97 different countries completed the survey, with the majority of those countries being located in Europe (74%). Even though completion of country of residence was not mandatory, it was provided in 1400 responses (97%).

The Angoff pass mark was 70.8 out of 120 points (59.0% threshold). The final pass mark, adjusted for clinical relevancy, was 52.8 out of 93.7 points (56.4% threshold). Overall, 513 respondents (35.4%) passed with the final pass mark. Pass rates differed per job category; results are shown in Fig. [1](#Fig1){ref-type="fig"}a. Intensivists scored best (42.5%), followed by fellows (36.1%), residents (24.7%) and nurses (5.8%). Without correcting for clinical relevance, respondents scored lower (nurses 3.9%, residents 19.2%, fellows 20.1%, intensivists 30.1%). Two-hundred and ninety-seven respondents (21%) reported consulting books (50%), the Internet (88%), and colleagues (49%). Test results from the 297 respondents that used additional resources are shown in Fig. [1](#Fig1){ref-type="fig"}d. For fellows and intensivists, this led to an increase of more than 20% of respondents achieving the pass mark; for nurses and residents, absolute pass rates improved by 226% and 59%, respectively. Results from intensivists were stratified by age and years of ICU experience (results shown in Fig. [1](#Fig1){ref-type="fig"}b, c). No clear trend in the age group was observed, although intensivists with less than 1 year of experience tended to score lower. Percentage scores per country can be found in Additional file [1](#MOESM1){ref-type="media"}. Only countries with at least three respondents are shown (51 out of 97, 52.6%).Fig. 1Scores of respondents. All results are percentages of respondents who passed based on the final pass mark adjusted for clinical relevance. **a** Survey results per job-title. **b** Intensivists' scores per age bin. **c** Intensivists' scores per years of experience, binned. **d** Results for respondents using additional resources to answer the questions

All survey questions with their model answers are shown in Table [2](#Tab2){ref-type="table"}. Angoff scores, clinical relevance, and pass rates are shown for each question. Overall, clinical relevance is high for all questions, except for questions 10 (56/100) and 12 (49/100) on calculating half-lives. Angoff scores for some questions were below 60/100, indicating questions were hard. Both questions that have low clinical relevance also showed low Angoff scores. Intensivists' pass rates per question range from 14.6 to 98.1%. Questions pertaining to Vancomycin excretion and antibiotic dosing in renal dysfunction showed high pass rates (90% and ≥ 90% for meropenem, ciprofloxacin, and ceftriaxone, respectively). Box 1 shows concise explanations for all questions.Table 2Questions and model answers with their respective Angoff scores and clinical relevanceQuestionAnswerAngoff score^a^Clinical relevance^a^Pass intensivists (%)1Are these antibiotics lipophilic or hydrophilic?VancomycinHydrophilic647460.2CeftriaxoneHydrophilic647444.6MeropenemHydrophilic647449.1CiprofloxacinLipophilic647437.22Which antibiotic is barely protein-bound?Meropenem427114.63For which antibiotic, using continuous infusion, is a loading dose least (!) importantMeropenem498318.34In case of severe renal dysfunction, how should the maintenance dose be adapted for these antibiotics?VancomycinLower the dose^b^749498.2CeftriaxoneLower the dose^b^689496.0MeropenemLower the dose^b^729490.0CiprofloxacinLower the dose^b^709470.45In case of severe renal dysfunction, how should the initial dose be adapted for these antibiotics?VancomycinNo adaptation759365.5CeftriaxoneNo adaptation729385.0MeropenemNo adaptation749364.1CiprofloxacinNo adaptation749366.96Which treatment goal is most relevant for these antibiotics?VancomycinAUC~0--24~/MIC578731.8CeftriaxoneT \> MIC608745.2MeropenemT \> MIC608749.9CiprofloxacinAUC0-24/MIC548731.67How are these antibiotics cleared?VancomycinMostly renally648990.0CeftriaxoneBoth renally and via liver/bile/feces598931.0MeropenemMostly renally608948.8CiprofloxacinBoth renally and via liver/bile/feces608930.78What are risk factors for augmented renal clearance?Cardiac arrestFalse668782.1Prolonged ICU admittanceFalse658773.3Advanced ageFalse658778.8Multi-traumaTrue658747.6Limited comorbidityTrue658733.19How do these parameters change in the initial phase of septic shock following adequate volume resuscitation?Volume of distributionIncreases618587.1ClearanceIncreases618535.510The volume of distribution of an antibiotic is 100 L. Clearance is 10 L/h. What is the half-life?About 7 h505641.611What happens to half-life if ...Clearance increasesDecreases647088.9Clearance decreasesIncreases657089.8Volume of distribution increasesIncreases637040.5Volume of distribution decreasesDecreases637039.412The half-life of an antibiotic is 3 h. When is steady state reached approximately following start of continuous infusion?13--17 h494938.8^a^Score out of 100^b^Multiple answers can be correct; see Box 1

Discussion {#Sec9}
==========

This is the first study to show that clinically relevant pharmacokinetic knowledge on antibiotic dosing among international intensive care professionals is insufficient. More than half of intensivists failed the test, while fellows, resident, and nurses had even lower scores. Thus, we have identified a major knowledge gap. Given the pivotal importance of adequate antibiotic dosing, this should be addressed.

The importance of pharmacokinetic principles to guide antibiotic dosing in critically ill patient is well recognized given the markedly altered and often changing pharmacokinetics in the critically ill \[[@CR6], [@CR8]\]. In particular, the DALI study showed that low antibiotic serum concentrations are associated with worse outcome in ICU patients \[[@CR8]\]. Therefore, it is surprising that pharmacokinetic education does not have a prominent role in medical education, even though clinical educational tools are readily available \[[@CR30]\]. The lack of pharmacokinetic expertise among intensive care professionals has likely contributed to the tolerance of standard dosing regimens for many antibiotics, even in the setting of intensive care medicine. This one-size-fits-all principle is also reflected in most national and international guidelines which fail to recommend individualized dosing strategies.

Education such as antimicrobial stewardship is a potential solution to improve pharmacokinetic expertise among intensive care professionals in order to optimize antibiotic dosing. However, large improvements in pharmacometric knowledge among intensive care professionals may not prove realistic. Causes include increasing workload in clinic \[[@CR31]\] and the growing body of medical literature to stay up to date with \[[@CR32]\]. An alternative solution could therefore be the extended use of therapeutic drug monitoring and increased support by clinical pharmacists and microbiologists. For vancomycin and the aminoglycosides, therapeutic drug monitoring has shown to increase efficacy and limit the occurrence of nephrotoxicity \[[@CR15], [@CR16]\]. Studies on therapeutic drug monitoring for the beta lactams are ongoing.

Automated pharmacokinetic modeling systems are another viable solution to tackle inadequate antibiotic exposure in the setting of intensive care medicine. The advent of electronic health record systems in most ICUs in resource-rich settings allows for continuous data feeds into integrated pharmacometric software, resulting in individual dosing recommendation at the bed side in real time \[[@CR33], [@CR34]\]. Other than therapeutic drug monitoring, these models could provide dosing advice based on the large amount of routinely collected clinical parameters rather than based on antibiotic samples alone. Advantages of these systems include immediate availability of dosing recommendations, i.e., even before the first dose, and the continuous correction of these recommendations at the touch of a button, based on a changing physiology in the critically ill. Evidently, safety and efficacy should be of unconditional importance when designing and implementing these systems. Therefore, such systems are currently still under investigation \[[@CR17]\].

This study has several strengths. First, all questions were based on the Cobatrice framework, which ensures close adherence to validated training and examination goals for intensivists. Second, the number of respondents was high and their background was heterogeneous, which extends the results to an international audience of ICU professionals. Third, the pass mark and clinical relevance were assessed by members of the ESICM examination committee and world-renowned experts on pharmacokinetics, which assures test validity. Scores were adjusted for clinical relevance as an extra step after Angoff scoring. The two questions that were rated hard (i.e., lower Angoff scores) concomitantly had lower clinical relevance scoring, which was therefore adjusted for in the final scores.

This study also has some limitations. Firstly, although the number of responses is high, the response rate is low. We asked people to disperse the survey to colleagues to increase the number of respondents, which also clouds the response rate. We risk that only people who felt comfortable with the questions completed the survey. This would imply, however, that our score is an overestimation. Although we asked people to refrain from using other resources to answer the questions, 21% sought help, which would also contribute to the overestimation of their personal knowledge on the subject. Additionally, the number of respondents per country might not be a representative sample of that country. We therefore refrain from drawing conclusions on a per country basis. The sample from multiple countries, however, implies trends are similar in an international population. Lastly, definitions of intensive care units vary worldwide due to available resources and historical trends. Concomitantly, definitions of job titles in the ICU differ per region or even within countries \[[@CR20], [@CR21]\]. We assumed, however, that the title *intensivist* is reserved globally for doctors taking care of patients threatened in their vital parameters, including sepsis and septic shock.

Conclusion {#Sec10}
==========

In conclusion, we showed that clinically relevant pharmacokinetic knowledge on antibiotic dosing among intensive care professionals is insufficient. This should be addressed, as suboptimal dosing strategies are associated with poorer outcomes. Options include extended use of therapeutic drug monitoring and pharmacist support as well as automated pharmacokinetics systems that provide dosing advice at the bedside in real time.

 {#Sec11}

Pharmacokinetics (the ancient Greek kinetikos meaning "putting in motion") deals with drug movement *into* (absorption), *within* (distribution), and *out of* (metabolism and excretion) the body. All of these are subject to major alterations in critically ill patients, necessitating adaptations in antibiotic dosing. The following brief educational overview addresses relevant pharmacokinetic changes and provides explanations for the answers to our test questions. Changes in absorption are omitted here as antibiotics should always be given intravenously in critically ill patients (100% absorption).

Distribution---antibiotic properties in the ICU (Q1, 2, 9, 11) {#Sec12}
--------------------------------------------------------------

The apparent volume of distribution (*V*~D~) of an antibiotic represents the necessary theoretical volume that contains the amount of administered drug to maintain the observed plasma concentration. *V*~D~ is derived by the amount of drug in the body/concentration measured in plasma. Size of antibiotic molecules, protein binding, and preference for aqueous (hydrophilic) or lipid (lipophilic) environments are properties of an antibiotic and influence antibiotic distribution and thus *V*~D~ (see Table [3](#Tab3){ref-type="table"}). Additionally, in critically ill septic patients, capillary leak, fluid resuscitation, and inotrope administration may decrease antibiotic concentrations and therefore increase *V*~D~. *V*~D~ is related to elimination, as increases in *V*~D~ indicate a decrease in elimination rate or an increase in half-life, as half-life is defined as t1/2 = 0.693 × *V*~D~/CL. An increase in *V*~D~ may be thought of as a lower plasma concentration presenting to the kidneys, clearing the plasma from the drug.Table 3Properties of antibiotics. Results from multiple online resources \[[@CR35], [@CR36]\]V~D~ (L)Lipo-/hydrophilicT~1/2~ (h)Protein bindingRenal clearanceTreatment goalVancomycin32--68Hydrophilic5--1155%75--90%AUC~0--24~/MICCeftriaxone7--12Hydrophilic885--95%60%*T* \> MICMeropenem11--27Hydrophilic12%50--75%*T* \> MICCiprofloxacin150--225Lipophilic4--720--40%75%AUC~0--24~/MIC

Metabolism---enzymatic function in the critically ill {#Sec13}
-----------------------------------------------------

The liver metabolizes drugs through phase I (oxidation---CYP enzymes) and phase II (conjugation) reactions. During sepsis, hepatic dysfunction, hypo- and hyperthermia, and altered hepatic blood flow, among others, may influence drug metabolism \[[@CR37]\]. The effect on antibiotic levels has not been completely elucidated.

Elimination---routes and dosage adaptations (Q3, 5, 7, 8, 9, 10, 11, 12) {#Sec14}
------------------------------------------------------------------------

Antibiotic elimination is mostly renal and to a lesser extent through hepatic routes, depending on antibiotic class. Hepatic elimination is generally related to cardiac output, which may be increased in sepsis. Likewise, augmented renal clearance may occur in the very early phase of critical illness, while impaired renal function is common at later stages \[[@CR38], [@CR39]\]. Risk factors for augmented renal clearance include young age, multi-trauma, and limited comorbidity, which could reflect the ability to recruit renal reserve \[[@CR38], [@CR39]\]. The time to reach steady state depends on half-life and thus is related to *V*~D~ and CL. Steady state is reached after 4 to 5 half-lives. This implies that for antibiotics with a long half-life, time to target concentration may be too long, necessitating a loading dose. This loading dose depends on *V*~D~ only and not on CL or rate of elimination. Therefore, in the setting of decreased clearance, e.g., because of renal failure, the loading dose should still be given in full. This can be thought of as the full *V*~D~ needed to be filled to quickly attain target concentration. An antibiotic with a low volume of distribution and short half-life such as meropenem will therefore quickly reach steady-state target concentration and requires no or low loading doses.

Treatment goals and dosing (Q4, 6) {#Sec15}
----------------------------------

Pre-clinical and clinical studies have identified pharmacokinetic treatment goals for antibiotics (Table [1](#Tab1){ref-type="table"}). Depending on antibiotic class, these may be concentration (Cmax/MIC) or time (*T* \> MIC) dependent, or a combination of both (AUC~0--24~/MIC) \[[@CR13]\]. In case of reduced clearance, e.g., because of renal failure, time-dependent treatment goals require prolongation of the dosing interval as maximum concentration---C~max~---and *T* \> MIC will remain unchanged. For AUC/MIC targets, the goal is to maintain AUC, possible through both a decrease in the maintenance dose and elongation of the interval. The smallest decrease in AUC is observed with a lowering of the dose and is therefore preferred. For some antibiotics, a decrease in renal clearance leads to an increase of hepatic clearance (ceftriaxone) in healthy subject, but this effect was not observed in a critically ill population \[[@CR40]\].

Additional file
===============

 {#Sec16}

Additional file 1:Result per country for intensivists (percentages and absolute numbers). (DOC 434 kb)
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